BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 29995825)

  • 1. Correlation between the dynamic contrast-enhanced MRI features and prognostic factors in breast cancer: A retrospective case-control study.
    Tao W; Hu C; Bai G; Zhu Y; Zhu Y
    Medicine (Baltimore); 2018 Jul; 97(28):e11530. PubMed ID: 29995825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement parameters on dynamic contrast enhanced breast MRI: do they correlate with prognostic factors and subtypes of breast cancers?
    Kim JY; Kim SH; Kim YJ; Kang BJ; An YY; Lee AW; Song BJ; Park YS; Lee HB
    Magn Reson Imaging; 2015 Jan; 33(1):72-80. PubMed ID: 25179138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative MRI morphology of invasive breast cancer: correlation with immunohistochemical biomarkers and subtypes.
    Bae MS; Seo M; Kim KG; Park IA; Moon WK
    Acta Radiol; 2015 Mar; 56(3):269-75. PubMed ID: 24558165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Magnetic resonance imaging of breast cancer and correlation with prognostic factors.
    Chang YW; Kwon KH; Choi DL; Lee DW; Lee MH; Lee HK; Yang SB; Kim Y; Seo DY
    Acta Radiol; 2009 Nov; 50(9):990-8. PubMed ID: 19863408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel.
    Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y
    J BUON; 2013; 18(1):57-63. PubMed ID: 23613389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expression discordances and clinical values of ER, PR, HER-2 and Ki-67 in primary and metastatic breast cancer].
    Yuan Y; Hu SN; Gao J; Yu Q; Hu YQ; Xu XY; Gao ZG; Zhang J; Zhang Z; Teng Y; Zhang LL
    Zhonghua Zhong Liu Za Zhi; 2019 Sep; 41(9):681-685. PubMed ID: 31550858
    [No Abstract]   [Full Text] [Related]  

  • 7. US-localized diffuse optical tomography in breast cancer: comparison with pharmacokinetic parameters of DCE-MRI and with pathologic biomarkers.
    Kim MJ; Su MY; Yu HJ; Chen JH; Kim EK; Moon HJ; Choi JS
    BMC Cancer; 2016 Feb; 16():50. PubMed ID: 26833069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation study between the magnetic resonance imaging features of breast cancer and expression of immune molecular subtypes.
    Long N; Ran C; Sun J; Hao CJ; Sui YB; Li J; Shi YX; Zou ZX; Qu YH
    Eur Rev Med Pharmacol Sci; 2020 Nov; 24(22):11518-11527. PubMed ID: 33275218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast MRI background parenchymal enhancement as an imaging bridge to molecular cancer sub-type.
    Dilorenzo G; Telegrafo M; La Forgia D; Stabile Ianora AA; Moschetta M
    Eur J Radiol; 2019 Apr; 113():148-152. PubMed ID: 30927939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiomic features of Pk-DCE MRI parameters based on the extensive Tofts model in application of breast cancer.
    Zhou X; Gao F; Duan S; Zhang L; Liu Y; Zhou J; Bai G; Tao W
    Phys Eng Sci Med; 2020 Jun; 43(2):517-524. PubMed ID: 32524436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of diffusion weighted imaging as supplement to dynamic contrast enhanced breast MRI: Can it help predict malignancy, histologic grade and recurrence?
    Roknsharifi S; Fishman MDC; Agarwal MD; Brook A; Kharbanda V; Dialani V
    Acad Radiol; 2019 Jul; 26(7):923-929. PubMed ID: 30293819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantification of breast tumor heterogeneity for ER status, HER2 status, and TN molecular subtype evaluation on DCE-MRI.
    Chang RF; Chen HH; Chang YC; Huang CS; Chen JH; Lo CM
    Magn Reson Imaging; 2016 Jul; 34(6):809-819. PubMed ID: 26968141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.
    Sinn HP; Schneeweiss A; Keller M; Schlombs K; Laible M; Seitz J; Lakis S; Veltrup E; Altevogt P; Eidt S; Wirtz RM; Marmé F
    BMC Cancer; 2017 Feb; 17(1):124. PubMed ID: 28193205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of neoadjuvant chemotherapy on expressions of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and Ki-67 in breast cancer.
    Qin Q; Gao F; Jiang W; Tan Q; Mo Q; Wei C
    Chin Med J (Engl); 2014; 127(18):3272-7. PubMed ID: 25266526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DCE-MRI texture analysis with tumor subregion partitioning for predicting Ki-67 status of estrogen receptor-positive breast cancers.
    Fan M; Cheng H; Zhang P; Gao X; Zhang J; Shao G; Li L
    J Magn Reson Imaging; 2018 Jul; 48(1):237-247. PubMed ID: 29219225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic Value of ER, PR, FR and HER-2-Targeted Molecular Probes for Magnetic Resonance Imaging in Patients with Breast Cancer.
    Jin YH; Hua QF; Zheng JJ; Ma XH; Chen TX; Zhang S; Chen B; Dai Q; Zhang XH
    Cell Physiol Biochem; 2018; 49(1):271-281. PubMed ID: 30138940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic contrast-enhanced and diffusion-weighted MRI of estrogen receptor-positive invasive breast cancers: Associations between quantitative MR parameters and Ki-67 proliferation status.
    Shin JK; Kim JY
    J Magn Reson Imaging; 2017 Jan; 45(1):94-102. PubMed ID: 27313102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in tumour heterogeneity based on dynamic contrast-enhanced MRI between tumour and peritumoural stroma for predicting Ki-67 status of invasive ductal carcinoma.
    He X; Zhou J; Ye S; Cheng Q; Miao H; Xu N; Li J; Pan Z; Cheng J; Wang M
    Clin Radiol; 2021 Jun; 76(6):470.e13-470.e22. PubMed ID: 33648758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis.
    Yan J; Liu XL; Han LZ; Xiao G; Li NL; Deng YN; Yin LC; Ling LJ; Yu XY; Tan CL; Huang XP; Liu LX
    Asian Pac J Cancer Prev; 2015; 16(2):823-9. PubMed ID: 25684532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
    Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
    World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.